Despite the POLARIX trial showing greater benefit for Pola-R-CHP in non-GCB DLBCL, experts don't use this biomarker for treatment decisions. The community's IHC-based testing is considered too discordant with the trial's GEP method to be clinically reliable.

A large number of mutations detected in a cancer patient's blood (ctDNA) often originate from non-cancerous hematopoietic stem cells, a phenomenon called clonal hematopoiesis. This necessitates sophisticated filtering, such as matched normal sequencing, to distinguish tumor-derived mutations from this biological noise.

In community SCLC care, molecular strategies are not monolithic. Genomic alteration testing (NGS) is ready for immediate use and can identify targets today. In contrast, neuroendocrine subtyping is still investigational and not yet clinically actionable, pending results from research studies.

Early data for BCL6 degraders in DLBCL is highly promising, representing a new class of targeted therapy. This approach, similar to degraders in breast and prostate cancer, could become a significant future treatment beyond established pathways.

Instead of just measuring the presence or quantity of proteins, new technology analyzes their physical proximity and co-localization on a cell's surface. This protein "geography" creates a unique spatial fingerprint that can more accurately distinguish healthy regenerating cells from residual cancer cells post-treatment.

The traditional "germinal center" (GC) classification for DLBCL is overly simplistic. Molecular analysis reveals distinct subtypes within GC, such as "dark zone" and "light zone" signatures, which have different prognoses and responses to targeted therapies like polatuzumab.

After standard immunotherapy biomarkers like PD-L1 and TMB proved ineffective in SCLC, the field shifted to a more direct approach. Novel therapies like the bispecific antibody tarlatumab target surface proteins such as DLL3, physically bridging immune cells to cancer cells without relying on predictive biomarkers.

Despite major advances in immunotherapy, patient selection remains crude compared to targeted therapies. PD-L1 is still the primary, yet imperfect, biomarker used. Dr. Carbone highlights an urgent need to develop better predictive biomarkers to customize immunotherapy regimens, as is standard for targeted agents.

Glioblastoma isn't a single mass but has finger-like 'tentacles' (diffuse infiltration) extending into brain tissue. It is also genetically and cellularly diverse, meaning a single-pathway drug will inevitably miss many tumor cells, leading to rapid recurrence and treatment failure.